Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.

Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.

PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.

2.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

3.

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel C, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA.

Int J Cancer. 2018 Mar 15;142(6):1102-1115. doi: 10.1002/ijc.31127. Epub 2017 Nov 6.

PMID:
29063589
4.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS.

Gynecol Oncol. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017. Epub 2017 Apr 6.

5.

Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.

Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-10. doi: 10.1093/jnci/djw251.

6.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J; HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators, Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP.

Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.

7.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

8.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

9.

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2016 Oct;26(8):1440-7. doi: 10.1097/IGC.0000000000000785.

10.

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

J Clin Oncol. 2016 Sep 1;34(25):3062-8. doi: 10.1200/JCO.2016.67.8722. Epub 2016 Jun 20.

11.

Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study.

Szender JB, Cannioto R, Gulati NR, Schmitt KL, Friel G, Minlikeeva A, Platek A, Gower EH, Nagy R, Khachatryan E, Mayor PC, Kasza KA, Lele SB, Odunsi K, Moysich KB.

J Low Genit Tract Dis. 2016 Jul;20(3):230-3. doi: 10.1097/LGT.0000000000000210.

12.

Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry.

Brightwell RM, Grzankowski KS, Kaur J, Poblete S, Miller A, Lele SB, Sucheston-Campbell L, Moysich K, Odunsi KO.

Am J Clin Exp Obstet Gynecol. 2015;2(1):39-44. Epub 2015 Feb 15.

13.

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.

Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D.

J Clin Oncol. 2015 Dec 20;33(36):4301-8. doi: 10.1200/JCO.2015.63.9518. Epub 2015 Nov 9.

14.

Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer.

Szender JB, Lele SB.

AMA J Ethics. 2015 Sep 1;17(9):843-8. doi: 10.1001/journalofethics.2015.17.9.stas1-1509. No abstract available.

15.

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer.

Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, Cannioto RA, Lele SB, Odunsi KO, Moysich KB.

J Low Genit Tract Dis. 2015 Jul;19(3):189-93. doi: 10.1097/LGT.0000000000000104.

16.

Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a gynecologic oncology service.

Szender JB, Frederick PJ, Eng KH, Akers SN, Lele SB, Odunsi K.

Int J Gynecol Cancer. 2015 Mar;25(3):512-20. doi: 10.1097/IGC.0000000000000378.

17.

Satisfaction with work-life balance among U.S. gynecologic oncologists, a cross-sectional study.

Szender JB, Grzankowski KS, Eng KH, Lele SB, Odunsi K, Frederick PJ.

Am J Clin Exp Obstet Gynecol. 2015;2(4):166-175.

18.

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Kolomeyevskaya NV, Lele SB, Miller A, Riebandt GC, Blum BL, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2015 Jan;25(1):42-8. doi: 10.1097/IGC.0000000000000307.

19.

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, Odunsi K.

PLoS One. 2014 Jan 7;9(1):e84941. doi: 10.1371/journal.pone.0084941. eCollection 2014.

21.

Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ.

Cancer Prev Res (Phila). 2012 Mar;5(3):435-43. doi: 10.1158/1940-6207.CAPR-11-0499. Epub 2012 Jan 13.

22.

Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer.

Shen J, Wang D, Gregory SR, Medico L, Hu Q, Yan L, Odunsi K, Lele SB, Ambrosone CB, Liu S, Zhao H.

Carcinogenesis. 2012 Mar;33(3):604-12. doi: 10.1093/carcin/bgs008. Epub 2012 Jan 10.

23.

Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy.

Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA.

World Neurosurg. 2011 Nov;76(5):477.e16-20. doi: 10.1016/j.wneu.2011.03.035.

PMID:
22152580
24.

Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment.

Beck TL, Singhal PK, Ehrenberg HM, Rose PG, Lele SB, Krivak TC, McBee WC Jr.

Gynecol Oncol. 2012 Apr;125(1):141-4. doi: 10.1016/j.ygyno.2011.10.010. Epub 2011 Nov 23.

PMID:
22119993
25.

Instituting a robot-assisted surgery programme at a tertiary care cancer centre.

duPont NC, Guru KA, Iskander GB, Odunsi K, Lele SB, Rodabaugh KJ.

Int J Med Robot. 2010 Sep;6(3):330-3. doi: 10.1002/rcs.339.

PMID:
20629199
26.

Novel genetic variants in miR-191 gene and familial ovarian cancer.

Shen J, DiCioccio R, Odunsi K, Lele SB, Zhao H.

BMC Cancer. 2010 Feb 18;10:47. doi: 10.1186/1471-2407-10-47.

27.

A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.

Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H.

Carcinogenesis. 2008 Oct;29(10):1963-6. doi: 10.1093/carcin/bgn172. Epub 2008 Jul 27.

PMID:
18660546
28.

Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature.

Smith R, Hicks D, Tomljanovich PI, Lele SB, Rajput A, Dunn KB.

Am Surg. 2008 Jan;74(1):59-61. Review.

PMID:
18274431
29.

A rare case of precoccygeal endometriosis.

Batt RE, Lele SB, Yeh J.

Obstet Gynecol. 2006 Jul;108(1):213; author reply 213-4. No abstract available.

PMID:
16816084
30.

Nezhat et al. Laparoscopic management of hepatic endometriosis: report of two cases and review of the literature.

Batt RE, Lele SB, Mitwally MF, Yeh J.

J Minim Invasive Gynecol. 2006 Jan-Feb;13(1):80; author reply 80-1. No abstract available.

PMID:
16431330
31.

Isolated hepatic endometriosis: as rare as hens' teeth, but sometimes you can learn a lot from a hen with teeth.

Batt RE, Lele SB, Mitwally MF, Yeh J.

Fertil Steril. 2003 Nov;80(5):1284; author reply 1284-5. No abstract available.

PMID:
14607592
32.

Pulmonary resection in metastatic uterine and cervical malignancies.

Anderson TM, McMahon JJ, Nwogu CE, Pombo MW, Urschel JD, Driscoll DL, Lele SB.

Gynecol Oncol. 2001 Dec;83(3):472-6.

PMID:
11733957
33.

Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery.

Wong C, Dai ZM, Lele SB, Natarajan N.

Eur J Gynaecol Oncol. 2000;21(1):70-3.

PMID:
10726624
34.

Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial enocarcinoma.

Heffner HM, Freedman AN, Asirwatham JE, Lele SB.

Eur J Gynaecol Oncol. 1999;20(1):8-12.

PMID:
10422671
35.

Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.

Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, Baker TR, Blumenson LE.

Gynecol Oncol. 1998 Sep;70(3):392-7.

PMID:
9790793
36.

Treatment of advanced ovarian carcinoma in the elderly.

Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM.

Gynecol Oncol. 1993 Apr;49(1):86-91.

PMID:
8482566
37.

Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.

Piver MS, Malfetano J, Baker TR, Lele SB, Marchetti DL.

Gynecol Oncol. 1989 Oct;35(1):69-72.

PMID:
2792905
38.

Photodynamic therapy in gynecologic malignancies.

Lele SB, Piver MS, Mang TS, Dougherty TJ, Tomczak MJ.

Gynecol Oncol. 1989 Sep;34(3):350-2.

PMID:
2475393
39.
40.
41.

Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.

Piver MS, Lele SB, Bakshi S, Parthasarathy KL, Emrich LJ.

Am J Clin Oncol. 1988 Oct;11(5):515-9.

PMID:
3177251
42.

Peritoneal papillary carcinoma.

Lele SB, Piver MS, Matharu J, Tsukada Y.

Gynecol Oncol. 1988 Oct;31(2):315-20. Review.

PMID:
2458994
43.

Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas.

Piver MS, Lele SB, Marchetti DL, Emrich LJ.

J Surg Oncol. 1988 Aug;38(4):233-9.

PMID:
3045423
44.

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.

Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ.

J Clin Oncol. 1988 Jun;6(6):983-9.

PMID:
3373267
45.

Serum alpha 1-acid glycoprotein in epithelial ovarian cancer.

Piver MS, Moyer M, Diakun K, Lele SB, Chu TM.

Gynecol Oncol. 1988 Mar;29(3):305-8.

PMID:
3345951
46.

Stage I uterine adenosarcoma: a report of six cases.

Baker TR, Piver MS, Lele SB, Tsukada Y.

J Surg Oncol. 1988 Feb;37(2):128-32.

PMID:
2830437
47.
48.

Cervical and vaginal cancer detection at a regional diethylstilbestrol (DES) screening clinic.

Piver MS, Lele SB, Baker TR, Sandecki A.

Cancer Detect Prev. 1988;11(3-6):197-202.

PMID:
3390844
49.

1.5-5 years of uninterrupted cis-diamminedichloroplatinum II chemotherapy for metastatic cervical cancer.

Piver MS, Lele SB, Patsner B, McPhee ME.

Gynecol Oncol. 1987 May;27(1):24-33.

PMID:
3570047
50.

Cisplatin plus VP16-213 in refractory ovarian carcinoma.

Lele SB, Piver MS, Malfetano J.

Am J Clin Oncol. 1987 Feb;10(1):21-2.

PMID:
3825989

Supplemental Content

Support Center